Renal Biomarker Market Overview from 2024 to 2034

Future Market Insights’ updated report on the renal biomarker ecosystem highlights various opportunities and growth spots for the coming decade. As per the analysis, the renal biomarker market is set to account for a current valuation of US$ 1,541.2 million in 2024.

Following this pattern, demand could rise and equate to a market valuation of US$ 3,031.8 million, with a moderate CAGR of 7% by 2034.

Attributes Details
Market Value for 2024 US$ 1,541.2 million
Market Value for 2034 US$ 3,031.8 million
Market Forecast CAGR for 2024 to 2034 7%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Historical Performance and Future Growth of the Renal Biomarker Market

Historical CAGR (2018 to 2023) 7.00%
Forecast CAGR (2024 to 2034) 7.00%

The renal biomarker market has exhibited robust historical performance, with a CAGR of 7.00% from 2018 to 2023. This steady growth can be attributed to the surge in the prevalence of kidney diseases, a boom in awareness about early diagnosis and treatment, and advancements in biomarker technologies.

The forecasted CAGR for the renal biomarker market from 2024 to 2034 remains at 7.00%, indicating continued growth momentum in the coming years. The forecast reflects the sustained demand for renal biomarkers as indispensable tools in clinical practice and research for the early detection, prognosis, and management of renal disorders.

Ongoing research and development efforts to discover novel biomarkers and improve diagnostic technologies are expected to contribute to market growth. The boom in adopting personalized medicine approaches and precision diagnostics will drive further investment in renal biomarker research and development, fueling market expansion over the forecast period.

Beacons to Guide the Renal Biomarker Market Forward

  • Continued innovation in biomarker discovery techniques, diagnostic assays, and imaging modalities is expected to propel the renal biomarker market forward.
  • Advancements such as high-throughput screening methods, omics technologies, and multiplexed assays enable the identification of new biomarkers with enhanced sensitivity and specificity, facilitating early disease detection and personalized treatment approaches.
  • The boom in focus on personalized medicine and precision diagnostics is set to propel the renal biomarker market.
  • Integrating biomarker data with clinical parameters enables more accurate risk stratification and treatment selection, driving the adoption of renal biomarkers in clinical practice.
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Key Factors Hampering the Renal Biomarker Market

  • Insufficient validation studies may limit the clinical utility of biomarkers, leading to skepticism among healthcare providers and hindering their integration into routine clinical practice.
  • Reimbursement challenges and regulatory requirements pose significant barriers to commercializing and adopting renal biomarker tests.
  • The complex regulatory landscape and stringent reimbursement policies can prolong the time to market and raise development costs for biomarker-based diagnostics.

Category-wise Insights

The below section shows the leading segment. Based on the biomarker type, the functional biomarker segment is accounted to hold a market share of 53.9% in 2024. Based on diagnostic technique, the enzyme linked immunosorbent assay segment is accounted to hold a market share of 46.7% in 2024.

Category Market Share in 2024
Functional Biomarker 53.9%
Enzyme Linked Immunosorbent Assay 46.7%

Functional Biomarker Segment to Hold a Significant Share in the Market

Based on biomarker type, the functional biomarker segment stands out, capturing a significant market share of 53.9%.

Functional biomarkers, such as serum creatinine and estimated glomerular filtration rate (eGFR), provide insights into kidney function and are essential for diagnosing and monitoring renal diseases. The widespread adoption reflects their critical role in clinical practice and research.

Enzyme Linked Immunosorbent Assay Segment to Hold a Dominant Share in the Market

Based on diagnostic technique, the enzyme linked immunosorbent assay segment is accounted to hold a market share of 46.7 % in 2024. The segment offers high sensitivity and specificity in detecting biomarkers in biological samples, making it a preferred choice for renal biomarker analysis.

The versatility and reliability contribute to its dominant position in the renal biomarker market, catering to the diagnostic needs of healthcare professionals and researchers alike.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Comparative View of Adjacent Markets

This section compares the renal biomarker industry, the renal function test market, and the enzyme substrates market.

The surge in demand for renal function tests to diagnose and monitor CKD augments market growth as healthcare providers prioritize preventive measures and early intervention strategies to mitigate the rising incidence of kidney diseases.

Enzyme substrates are essential tools in drug discovery, biochemical assays, and biotechnology applications, facilitating the measurement of enzyme activity, drug screening, and target validation.

Renal Biomarker Market:

Attributes Renal Biomarker Market
CAGR from 2024 to 2034 7%
Opportunity Integrating artificial intelligence (AI) and machine learning algorithms into biomarker analysis and interpretation.
Key Trends The surge in adoption of point-of-care testing (POCT) solutions for rapid and decentralized diagnosis of renal conditions.

Renal Function Test Market:

Attributes Renal Function Test Market
CAGR from 2023 to 2033 5.5%
Opportunity Expansion of home-based testing solutions for monitoring kidney function and managing chronic kidney diseases (CKD).
Key Trends Adopting multi-marker or panel-based assays for comprehensive assessment of kidney function.

Enzyme Substrates Market:

Attributes Enzyme Substrates Market
CAGR from 2023 to 2033 5.8%
Opportunity An opportunity for the enzyme substrate market lies in expanding therapeutic applications beyond diagnostic use.
Key Trends The development of novel substrate technologies with improved specificity, stability, and performance characteristics.

Country-wise Insights

The table describes the top five countries ranked by revenue, with the United Kingdom holding the top position. The United Kingdom dominates the renal biomarker market through its advanced healthcare infrastructure, robust research ecosystem, and extensive clinical expertise.

Renowned academic institutions, leading healthcare providers, and innovative biotechnology companies collaborate to drive biomarker research, development, and adoption, positioning the United Kingdom at the forefront of renal healthcare innovation.

Forecast CAGRs from 2024 to 2034

Countries CAGR
The United States 7.8%
The United Kingdom 8.5%
France 6.7%
China 7.6%
India 6.9%

Extensive Usage of Renal Biomarkers Impresses the United States Market

In the United States, the renal biomarker market is utilized in clinical settings to detect, diagnose, and monitor kidney diseases such as chronic kidney disease (CKD), acute kidney injury (AKI), and renal transplant rejection.

Renal biomarkers are important in assessing kidney function, identifying patients at risk of kidney damage, and guiding treatment decisions. Renal biomarkers are extensively used in the research domain in academic institutions and biopharmaceutical companies for studying renal physiology, disease mechanisms, and therapeutic interventions.

Clinical Practice Boosts the Renal Biomarkers Market in the United Kingdom

Renal biomarkers are widely used in clinical practice to evaluate kidney function and diagnose renal disorders. General practitioners, nephrologists, and healthcare providers utilize renal biomarker tests for routine screening, disease monitoring, and risk stratification in patients with CKD, diabetes, etc.

Academic institutions and clinical laboratories employ renal biomarkers for translational research, biomarker discovery, and validation studies to improve renal healthcare outcomes and develop novel diagnostic and therapeutic strategies.

Academic Research Centers Rising in Popularity is Ensuring Market Growth in France

In France, renal biomarkers have extensive applications in clinical and research settings to address the growing burden of kidney diseases and improve patient care. Clinicians rely on renal biomarker tests to assess kidney function, diagnose renal disorders, and monitor disease progression in diverse patient populations.

Academic research centers and biotechnology companies utilize renal biomarkers to investigate disease mechanisms, identify therapeutic targets, and develop innovative diagnostic assays and therapeutic interventions for kidney diseases.

Developing Medical Centers in China Improves the Market

The renal biomarker market in China is predominantly utilized in clinical laboratories, hospitals, and medical centers for diagnosing and managing kidney diseases.

Renal biomarker tests are vital in evaluating kidney function, detecting renal damage, and guiding treatment decisions in patients with CKD, AKI, and other renal disorders.

In academic and research institutions, renal biomarkers are utilized for studying renal pathophysiology, biomarker discovery, and translational research to advance our understanding of kidney diseases and develop novel therapeutic approaches.

Rising Affluence of Renal Disorders Gives Rise to a Greater Demand for Renal Biomarkers

Similarly, in India, renal biomarkers are extensively used in clinical practice to assess kidney function, diagnose renal disorders, and monitor disease progression in patients with CKD, diabetes, and other renal conditions.

Renal biomarker tests are integral to routine healthcare screenings, specialty consultations, and preoperative assessments in hospitals and healthcare facilities nationwide.

Academic research institutes and biotechnology companies leverage renal biomarkers for conducting basic and translational research to improve renal healthcare outcomes and address the unmet needs of patients with kidney diseases.

Competitive Landscape

A mix of multinational corporations, biotechnology companies, and academic research institutions characterizes the competitive landscape of the renal biomarker market. The companies focus on research and development to innovate new biomarkers, improve diagnostic accuracy, and expand their market reach.

Partnerships, collaborations, and strategic acquisitions are common strategies players employ to strengthen their market position and capitalize on emerging opportunities in the renal biomarker market.

Some of the key developments are

  • In December 2022, Journey Biosciences, Inc. unveiled NaviDKD, a pioneering biomarker-based blood test designed to predict long-term kidney complications in individuals with diabetes. The groundbreaking screening technology offered an early warning system for the development of kidney damage in diabetic patients, addressing a critical need for proactive intervention and improved patient outcomes.
  • In March 2022, Renalytix plc introduced myIntelX, a state-of-the-art provider access portal aimed at enhancing access to KidneyIntelX prognostic testing. This blood-based biomarker test enabled more precise identification of type 2 diabetes patients at high risk of rapid kidney disease progression.

Key Coverage in the Renal Biomarker Industry Report

  • Adjacent Study on Renal Biomarker Market
  • Asia Pacific Renal Biomarker Market
  • Renal Biomarker Market Size, Current Insights, and Demographic Trends
  • Global Renal Biomarker Market Demand
  • Key Opportunities of the Global Renal Biomarker Market

Report Scope

Attributes Details
Estimated Market Size in 2024 US$ 1,541.2 million
Projected Market Valuation in 2034 US$ 3,031.8 million
Value-based CAGR 2024 to 2034 7%
Forecast Period 2024 to 2034
Historical Data Available for 2018 to 2023
Market Analysis Value in US$ million
Key Regions Covered
  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia and Pacific
  • East Asia
  • The Middle East and Africa
Key Market Segments Covered
  • Biomarker
  • Diagnostic Technique
  • End User
  • Region
Key Countries Profiled
  • The United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Italy
  • Russia
  • Poland
  • Czech Republic
  • Romania
  • India
  • Bangladesh
  • Australia
  • New Zealand
  • China
  • Japan
  • South Korea
  • GCC countries
  • South Africa
  • Israel
Key Companies Profiled
  • Abbott Laboratories
  • BioPorto Diagnostics AS
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific Inc.
  • Nexelis (Pacific Biomarkers)
  • BioMérieux
  • Sphingotec GmbH
  • Randox Laboratories Ltd
  • Siemens Healthineers AG
  • Beckman Coulter Inc. (Danaher Corporation)
  • Bio-Rad Laboratories Inc.

Key Segments

By Biomarker:

  • Functional Biomarker
  • Serum Creatinine
  • Serum Cystatin C
  • Urine Albumin
  • Up-regulated Proteins
  • Neutrophil Gelatinase-Associated Lipocalin
  • Kidney Injury Molecule-1
  • Interleukin-18
  • Others

By Diagnostic Technique:

  • Enzyme Linked Immunosorbent Assay (ELISA)
  • Particle-Enhanced Turbidimetric Immunoassay (PETIA)
  • Colorimetric Assay
  • Chemiluminescent Enzyme Immunoassay (CLIA)
  • Liquid Chromatography-Mass Spectrometry (LS-MS)

By End User:

  • Diagnostic Labs
  • Outpatient Clinics
  • Research Centers
  • Hospitals

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia and Pacific
  • East Asia
  • The Middle East and Africa

Frequently Asked Questions

What is the expected worth of the renal biomarker market in 2024?

As of 2024, the market for renal biomarkers is expected to be valued at US$ 1,541.2 million.

What is the market potential for renal biomarkers?

The renal biomarker market is projected to expand at a CAGR of 7% between 2024 and 2034.

Which biomarker type segment dominates the renal biomarker market?

The functional biomarker segment is projected to dominate the industry, with a market share of 53.9% in 2024.

What is the anticipated market value for renal biomarkers in 2034?

By 2034, the market value of the renal biomarker is expected to reach US$ 3,031.8 million.

Which country is likely to dominate the renal biomarker market?

The United Kingdom is likely the top-performing market, with a CAGR of 8.5%.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034

    4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Biomarker

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Biomarker, 2019 to 2023

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Biomarker, 2024 to 2034

        5.3.1. Functional Biomarker

            5.3.1.1. Serum Creatinine

            5.3.1.2. Serum Cystatin C

            5.3.1.3. Urine Albumin

        5.3.2. Up-Regulated Proteins

            5.3.2.1. Neutrophil Gelatinase-Associated Lipocalin

            5.3.2.2. Kidney Injury Molecule-1

            5.3.2.3. Interleukin-18

        5.3.3. Others

    5.4. Y-o-Y Growth Trend Analysis By Biomarker, 2019 to 2023

    5.5. Absolute $ Opportunity Analysis By Biomarker, 2024 to 2034

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Diagnostic Technique

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Diagnostic Technique, 2019 to 2023

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnostic Technique, 2024 to 2034

        6.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

        6.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

        6.3.3. Colorimetric Assay

        6.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

        6.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

    6.4. Y-o-Y Growth Trend Analysis By Diagnostic Technique, 2019 to 2023

    6.5. Absolute $ Opportunity Analysis By Diagnostic Technique, 2024 to 2034

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2019 to 2023

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2024 to 2034

        7.3.1. Diagnostic Labs

        7.3.2. Outpatient Clinics

        7.3.3. Research Centers

        7.3.4. Hospitals

    7.4. Y-o-Y Growth Trend Analysis By End User, 2019 to 2023

    7.5. Absolute $ Opportunity Analysis By End User, 2024 to 2034

8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Biomarker

        9.2.3. By Diagnostic Technique

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Biomarker

        9.3.3. By Diagnostic Technique

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Biomarker

        10.2.3. By Diagnostic Technique

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Biomarker

        10.3.3. By Diagnostic Technique

        10.3.4. By End User

    10.4. Key Takeaways

11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Biomarker

        11.2.3. By Diagnostic Technique

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Biomarker

        11.3.3. By Diagnostic Technique

        11.3.4. By End User

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Biomarker

        12.2.3. By Diagnostic Technique

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Biomarker

        12.3.3. By Diagnostic Technique

        12.3.4. By End User

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Biomarker

        13.2.3. By Diagnostic Technique

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Biomarker

        13.3.3. By Diagnostic Technique

        13.3.4. By End User

    13.4. Key Takeaways

14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Biomarker

        14.2.3. By Diagnostic Technique

        14.2.4. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Biomarker

        14.3.3. By Diagnostic Technique

        14.3.4. By End User

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Biomarker

        15.2.3. By Diagnostic Technique

        15.2.4. By End User

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Biomarker

        15.3.3. By Diagnostic Technique

        15.3.4. By End User

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2023

            16.1.2.1. By Biomarker

            16.1.2.2. By Diagnostic Technique

            16.1.2.3. By End User

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2023

            16.2.2.1. By Biomarker

            16.2.2.2. By Diagnostic Technique

            16.2.2.3. By End User

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2023

            16.3.2.1. By Biomarker

            16.3.2.2. By Diagnostic Technique

            16.3.2.3. By End User

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2023

            16.4.2.1. By Biomarker

            16.4.2.2. By Diagnostic Technique

            16.4.2.3. By End User

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2023

            16.5.2.1. By Biomarker

            16.5.2.2. By Diagnostic Technique

            16.5.2.3. By End User

    16.6. UK

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2023

            16.6.2.1. By Biomarker

            16.6.2.2. By Diagnostic Technique

            16.6.2.3. By End User

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2023

            16.7.2.1. By Biomarker

            16.7.2.2. By Diagnostic Technique

            16.7.2.3. By End User

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2023

            16.8.2.1. By Biomarker

            16.8.2.2. By Diagnostic Technique

            16.8.2.3. By End User

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2023

            16.9.2.1. By Biomarker

            16.9.2.2. By Diagnostic Technique

            16.9.2.3. By End User

    16.10. Poland

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2023

            16.10.2.1. By Biomarker

            16.10.2.2. By Diagnostic Technique

            16.10.2.3. By End User

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2023

            16.11.2.1. By Biomarker

            16.11.2.2. By Diagnostic Technique

            16.11.2.3. By End User

    16.12. Czech Republic

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2023

            16.12.2.1. By Biomarker

            16.12.2.2. By Diagnostic Technique

            16.12.2.3. By End User

    16.13. Romania

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2023

            16.13.2.1. By Biomarker

            16.13.2.2. By Diagnostic Technique

            16.13.2.3. By End User

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2023

            16.14.2.1. By Biomarker

            16.14.2.2. By Diagnostic Technique

            16.14.2.3. By End User

    16.15. Bangladesh

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2023

            16.15.2.1. By Biomarker

            16.15.2.2. By Diagnostic Technique

            16.15.2.3. By End User

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2023

            16.16.2.1. By Biomarker

            16.16.2.2. By Diagnostic Technique

            16.16.2.3. By End User

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2023

            16.17.2.1. By Biomarker

            16.17.2.2. By Diagnostic Technique

            16.17.2.3. By End User

    16.18. China

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2023

            16.18.2.1. By Biomarker

            16.18.2.2. By Diagnostic Technique

            16.18.2.3. By End User

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2023

            16.19.2.1. By Biomarker

            16.19.2.2. By Diagnostic Technique

            16.19.2.3. By End User

    16.20. South Korea

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2023

            16.20.2.1. By Biomarker

            16.20.2.2. By Diagnostic Technique

            16.20.2.3. By End User

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2023

            16.21.2.1. By Biomarker

            16.21.2.2. By Diagnostic Technique

            16.21.2.3. By End User

    16.22. South Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2023

            16.22.2.1. By Biomarker

            16.22.2.2. By Diagnostic Technique

            16.22.2.3. By End User

    16.23. Israel

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2023

            16.23.2.1. By Biomarker

            16.23.2.2. By Diagnostic Technique

            16.23.2.3. By End User

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Biomarker

        17.3.3. By Diagnostic Technique

        17.3.4. By End User

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Abbott Laboratories

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. BioPorto Diagnostics AS

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. F. Hoffmann-La Roche AG

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Thermo Fisher Scientific Inc.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Nexelis (Pacific Biomarkers)

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. BioMérieux

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Sphingotec GmbH

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Randox Laboratories Ltd

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Siemens Healthineers AG

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Beckman Coulter Inc. (Danaher Corporation)

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

        18.1.11. Bio-Rad Laboratories Inc.

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Biomarker Discovery Outsourcing Service Market

March 2024

REP-GB-19255

299 pages

Healthcare

Renal Function Test Market

December 2017

REP-GB-5845

September 2023

317 pages

Healthcare

Enzyme Substrates Market

September 2024

REP-GB-13650

Upcoming

Explore Healthcare Insights

View Reports